Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Shareholder Meeting (July 2025)
11 slides from Chimeric Therapeutics's shareholder meeting presentation, Jul 23, 2025
Slide 1: Pioneers in Cell Therapy
For personal use only CHI MERIC THE RAP EU TICS 25 20 PIONEERS IN CELL THERAPY CHIMERIC ASX: CHM
Slide 2: Disclaimer
DISCLAIMER Certain statements contained in this presentation, including, any obligation to update any such factors or to publicly without limitation, statements containing the words “believes,” announce the results of any revisions to any of the forward- “plans,” “expects,” “anticipates,” and words
Slide 3: FY25 in Summary
FY25 IN SUMMARY 3 $16.6m raised including $5.6m from US Family Office For personal use only Corporate Lind facility paid out in full by end of July 2025. Significant headcount and cost reductions CHI MERIC THE RAP EU TICS Trial commenced: 5 patients treated CHM CDH17 Dose level 1 completed: Stable d
Slide 4: CHM CDH17
For personal use only CHI MERIC THE RAP EU TICS 25 20 CHM CDH17 ASX: CHM
Slide 5: Clinical Preliminary Results: CHM CDH17 Dose Level 50m Cells
CLINICAL PRELIMINARY RESULTS 5 CHM CDH17 DOSE LEVEL 1 For personal use only 50m Cells Tumour Type Status Patient 1 CRC No follow up CHI MERIC THE RAP EU TICS Patient 2 NET Stable Disease until day 150 progression Patient 3 CRC Stable Disease at day 150 Patient 4 CRC Progressive Disease at day 28 20
Slide 6: Clinical Preliminary Results: CHM CDH17 Dose Level 150m Cells
CLINICAL PRELIMINARY RESULTS 6 CHM CDH17 DOSE LEVEL 2 For personal use only 150m Cells Tumour Type Status CHI MERIC THE RAP EU TICS Patient 5 CRC DLT Passed. Pending DAY 28 SCAN Patient 6 NET Manufactured to be treated Patient 7 NET Manufactured to be treated 20 25 CRC= Colorectal Cancer (Bowel Canc
Slide 7: CHM CORE-NK
For personal use only CHI MERIC THE RAP EU TICS 25 20 CHM CORE-NK ASX: CHM
Slide 8: CHM CORE-NK Frontline Phase Study Results
8 CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS Complete response in AML in two patient of first three dosed For personal use only 2 / 3 patients CORE-NK DIAGNOSIS: AML INFUSION CHI MERIC THE RAP EU TICS Not eligible for Chemo or Stem Patient Doses + SOC Cell Transplant COMPLETE RESPONSE i SAFETY: No
Slide 9: CHM: Broad Portfolio
CHM: BROAD PORTFOLIO 3 Novel cell therapies; 4 Clinical Trials For personal use only CHM CDH17 CHM CORE-NK CHM CLTX CAR-T ‘OFF THE SHELF’ NK CHI MERIC THE RAP EU TICS PHASE 1B PHASE 1B TRIAL OPEN TRIAL OPEN PHASE 1/2 TRIAL OPEN PHASE 1B TRIAL 4 sites active MD Anderson Case Western 1 site active 20
Slide 10: Investment Highlights
INVESTMENT HIGHLIGHTS 4 4 Phase 1 clinical trials For personal use only CORPORATE PROFILE Multiple clinical updates Exchange ASX: CHM CHI MERIC THE RAP EU TICS Experienced leadership team Share Price $0.005 52 Week Range $0.004 - 0.047 the ONLY CDH17 CAR-T in clinical trials Market Cap Approx $10m F
Slide 11: Chimeric: Pioneers in Cell Therapy
For personal use only CHIMERIC CHI MERIC THE RAP EU TICS PIONEERS IN CELL THERAPY investors@chimerictherapeutics.Com ASX: CHM 20 25
Chimeric Therapeutics — Shareholder Meeting (July 2025) on 6ix